, Volume 470, Issue 7, pp 1932-1940
Date: 13 Dec 2011

Fixation Failures of Dual Mobility Cups: A Mid-term Study of 2601 Hip Replacements

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

The use of dual-mobility cups has increased because of a low rate of dislocations combined with a 96% 15-year survival rate. However, late cup migrations have been attributed to their fixation (tripod - exact fit with two pegs and one extraacetabular screw) and the absence of porous coating. In a second-generation device, the designs were modified to achieve press-fit fixation and a layer of titanium beads was sintered on stainless steel cups.

Questions/purposes

We therefore (1) determined the midterm survival of press-fit, grit-blasted, second-generation cups with or without additional screws, compared with original tripod and (2) compared survival of grit-blasted dual-mobility cups with bimetallic porous-coated cups.

Methods

From a multiinstitutional trial, we reviewed 2408 patients with osteoarthritis implanted with 2601 prostheses of seven designs of a second-generation dual-mobility cup. The criteria for failure were migration, widening radiolucencies in any zone of the interface, or revision for cup loosening. The minimum followup was 5 years (mean, 7.7 years; range, 5–11 years).

Results

The 8-year survival rate of press-fit, grit-blasted cups was lower than that for press-fit, grit-blasted cups fixed with screws (91% versus 100%) and for tripod fixation (98%). The 8-year survival rate of press-fit, grit-blasted cups was less than that for press-fit, porous-coated cups made of the same alloy (91% versus 95%).

Conclusions

The data suggested primary fixation of grit-blasted dual-mobility cups should be secured with screws. Porous coating sintered on the convex side improved midterm survivorship. No deleterious effect of metallosis resulted from sintered titanium beads on stainless steel. Long-term followup is required to confirm these findings.

Level of Evidence

Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

The authors (PM, RP, FF, MF) certify that they have received payments of royalties and benefits, an amount in excess of $10,000 from Serf, Decines, France (RP, FF, MF), Ceramconcept, Paris, France (PM, FF), and Wright Medical EMEA, Amstelveen, the Netherlands (PM), all companies related to this work.
All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request.
Clinical Orthopaedics and Related Research neither advocates nor endorses the use of any treatment, drug or device. Readers are encouraged to always seek additional information, including FDA-approval status, of any drug or device prior to clinical use.
Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.